Source: The Hill
“The Trump administration announced its newest pharmaceutical agreement under its Most Favored Nation policy Thursday, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices. According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products for a monthly starting price starting of $245 for people on Medicare and Medicaid, as well as those who use the TrumpRX platform expected to launch early next year. Oral GLP-1s will also be sold through the same avenues at a starting price of $149 per month.” (11/06/25)
https://thehill.com/policy/healthcare/5593083-trump-administration-glp-1-novo-nordisk-eli-lilly